Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Cy, Lee; Tien, Hwei‐Fang; Hu, Chung-Yi; Chou, Wen‐Chien; Lin, Liang-In

doi:10.1038/sj.bjc.6603966

Cited by 39 publications

(36 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The regulatory role of Ang-1 and Ang-2 in tumor angiogenesis remains controversial due to the conflicting roles of both angiopoietins in angiogenesis [11]. Ang-1 activates Tie2 more strongly than does Ang-2; thus, some of the effects of Ang-2 could result from the inhibition of Ang-1 signaling [1,12]. Ang-1-Tie2 signaling is thought to limit angiogenesis in mature vessels [1].…”

Section: Introductionmentioning

confidence: 99%

Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis

Atesoglu

Tarkun

Mehtap

et al. 2015

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Molecular balance between Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) has important effects in tumor angiogenesis. Ang-2 was shown to be elevated and proved to be a prognostic factor in acute myeloid leukemia (AML). To date studies revealed increased angiogenesis in bone marrows (BMs) of both myeloproliferative neoplasm (MPN) and AML patients. We conducted this study to demonstrate circulating levels of Ang-1 and Ang-2 in MPN patients since no data exists in literature. Thirty-three newly diagnosed MPN, 27 newly diagnosed AML patients and 25 controls (HC) were enrolled and Angiopoietin levels were determined with ELISA. We found that Ang-1 levels were higher whereas Ang-2 levels were lower in MPN and HC when compared to AML. Our results suggest that though angiogenesis is increased in both AML and MPN, angiopoietin serum level profile of the two diseases are different, and MPN patients have similar Ang-1 and Ang-2 levels as HC. We conclude that, according to our results Ang-1 and Ang-2 do not only regulate tumor angiogenesis and the difference between angiopoietin levels of acute and chronic myeloid neoplasms could be a reflection of other effects of these growth factors on tumor malignancy.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis

Atesoglu

Tarkun

Mehtap

et al. 2015

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…The threeyear survival rate for AML patients with high levels of Ang-2 was only 14.7% compared to 64.7% for those with low Ang-2 levels. Furthermore, Lee et al [20] reported that AML patients with lower Ang-2 and Tie-2 levels displayed a survival advantage.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of soluble angiopoietin-2 and soluble Tie-2 in Egyptian patients with acute myeloid leukemia

Attia

Hazzaa²,

Essa³

et al. 2010

Turk J Hematol

View full text Add to dashboard Cite

Objective: Angiogenesis plays a critical role in the development and growth of solid tumors and hematologic malignancies. The system involving angiopoietin-2 [Ang-2] and its receptor Tie-2 appears to play an important role in tumor angiogenesis and in the biology of hematological and non-hematological malignancies. We evaluated the levels of soluble (s)Ang-2 and sTie-2 in acute myeloid leukemia (AML) patients and investigated the impact of their circulating levels on the overall survival in those patients. Materials and Methods: Ang-2 and Tie-2 were measured in plasma samples from AML patients and controls using enzyme-linked immunosorbent assay (ELISA). Results: The levels of sAng-2 and sTie-2 were significantly higher in AML patients (2382.1±1586.1 pg/ml and 6.74±3.47 ng/ml, respectively) than in controls (649.5±402.6 pg/ml and 2.63±0.57 ng/ml, respectively; p<0.01). AML patients with high levels of sAng-2 and sTie-2 ( 2500 pg/ml and 8 ng/ml, respectively) had significantly shorter overall survival than those patients with low levels (<2500 pg/ml and <8 ng/ml, respectively). Conclusion: The results of our study demonstrated the prognostic significance of circulating sAng-2 and sTie-2 in AML patients. Modulation of the angiopoietin / Tie-2 axis may be a promising approach to improve the outcome in those patients. (Turk J Hematol 2010; 27: 282-8) Key words: Ang-2, Tie-2, AML, ELISA

show abstract

“…VEGF can influence and regulate the malignant behavior of leukemic cells via paracrine and autocrine pathways [12], and high levels of plasma VEGF in AML patients indicate a poor prognosis [13]. A high VEGF level in childhood AML is also an independent factor indicating poor prognosis [14], suggesting that VEGF inhibition can have potential therapeutic effects on AML.…”

Section: Discussionmentioning

confidence: 99%

Effects of Thalidomide Combined with Interferon on Inhibiting Kasumi-1 Cell Proliferation

Fan

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

with CR will relapse, with a long-term survival of less than 10%. In addition, treatment-related side effects are among the main factors limiting the clinical efficacy for AML treatment. It is of great practical significance to explore safe and effective new treatment options. Steins et al. [1] reported that the effective rate of thalidomide monotherapy in AML was 25% and that this treatment could improve transfusion dependence in patients.With improvements in treatment, the complete remission (CR) rate of young patients with acute myeloid leukemia (AML) can be as high as 70% to 80%, and after subsequent consolidation chemotherapy or hematopoietic stem cell transplantation (HSCT), the 5-year overall survival (OS) rate is approximately 40% to 45%. However, the treatment effect is poor in high-risk and el- Objectives. The aim of this study was to investigate the effects and its mechanism of thalidomide and IFN on inhibiting the proliferation of Kasumi-1 cells. Material and Methods. Thalidomide, IFN and a combination of both drugs were used to treat Kasumi-1 cells. The inhibition of cell proliferation and the apoptosis rate were measured. Vascular endothelial growth factor levels and the expression of apoptosis-related proteins were detected by ELISA and Western blotting, respectively. Results. Thalidomide and IFN could both inhibit Kasumi-1 cell proliferation in a dose-dependent manner. When Kasumi-1 cells were treated with thalidomide 350 μg/mL or IFN1400 U/mL for 48 h, the proliferation inhibition rates were (48.8 ± 4.64)% and (50.19 ± 2.59)% and the rates of apoptosis were (14.68 ± 2.61)% and (21.71 ± 0.71)%, respectively; when treated with a combination, the cell proliferation inhibition rate and apoptotic rate were statistically significantly higher than both the control group and the groups treated with a single drug. The ELISA assay revealed that both 350 μg/mL of thalidomide and 1400 U/mL of IFN could reduce the VEGF levels in cell culture supernatants; the two-drug combination group had a further decreased VEGF concentration. Forty-eighthour treatment of thalidomide 350 μg/mL and IFN 1400 U/mL could significantly decrease Bcl-2 expression and increase the expression levels of phosphor-P38, BAX, cytochrome c, and cleaved caspase-3, -8, and -9 as compared to the control group. The combination group exhibited significantly greater extents of reduction in Bcl-2 protein and increases in p-P38, BAX, and cytochrome c, and cleaved caspase-3, -8, and -9 protein expression as compared to the single drug groups. Conclusions. Thalidomide and IFN can synergistically inhibit Kasumi-1 cell proliferation, which is possibly achieved through the mitochondrial and death receptor pathways and through the activation of the P38 signaling pathway to induce apoptosis and by inhibiting Kasumi-1 cell autocrine VEGF secretion (Adv Clin Exp Med 2016, 25, 3, 403-408).

show abstract

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia

Cited by 39 publications

References 33 publications

Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis

Serum Angiopoietin Levels are Different in Acute and Chronic Myeloid Neoplasms: Angiopoietins do not only Regulate Tumor Angiogenesis

Prognostic value of soluble angiopoietin-2 and soluble Tie-2 in Egyptian patients with acute myeloid leukemia

Effects of Thalidomide Combined with Interferon on Inhibiting Kasumi-1 Cell Proliferation

Contact Info

Product

Resources

About